promo_leaderboard Ad
‹ All stocks
RVMD

Revolution Medicines

RVMD · NASDAQ · Healthcare
$164.87
▼ $2.01 (-1.20%)
$164.87 $179.43 $194.00 $208.56 $164.87 Sep 2026 Oct 2026 Nov 2026
Day range
$163.62 – $167.99
Year range
$67.27 – $224.31
Open
$166.78
Previous close
$166.87
Market cap
$35.66B
Volume (24h)
$133.2K
Volume (52w)
$21.96M
Performance
7D
▼ -14.60%
1M
▼ -9.49%
3M
▼ -23.20%
6M
▲ 7.24%
1Y
▲ 138.45%
YTD
▲ 108.64%
3Y
▲ 658.70%
5Y
▲ 447.72%
All-time
▲ 470.47%
Key statistics
P/E ratio
-18.10
EPS (TTM)
$-9.11
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
216.3M
About Revolution Medicines

Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.

Visit website
Country: United States of America
Related news
More in Healthcare